Emadi, Ashkan <br/><br/>
Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia.  [electronic resource] 

 -  American journal of hematology  May 2015 
 - E77-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1096-8652 
<br/><br/><label>Standard No.: </label>10.1002/ajh.23965  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Age Factors<br/>Aged<br/>Antimetabolites, Antineoplastic--therapeutic use<br/>Azacitidine--analogs & derivatives<br/>DNA Modification Methylases--antagonists & inhibitors<br/>Decitabine<br/>Female<br/>Genotype<br/>Humans<br/>Isocitrate Dehydrogenase--genetics<br/>Leukemia, Myeloid, Acute--diagnosis<br/>Male<br/>Mutation<br/>Odds Ratio<br/>Prognosis<br/>Remission Induction<br/>Retrospective Studies<br/>Sex Factors